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Microvascular pericytes are able to generate multiple mesenchymal cell types, including skeletal muscle
myoblasts. Cappellari et al. (2013) report in this issue of Developmental Cell that myoblasts can return the
favor by generating pericytes via the action of Dll4 Notch ligand and PDGF-BB.Pericytes are the microvascular mural
cell counterparts of smooth muscle cells
in larger vessels, partnering with vascular
endothelial cells during vessel mor-
phogenesis and maturation. Extensive
crosstalk occurs between pericytes and
endothelial cells throughout all phases of
vessel development, mediating not only
initial interactions between the two cell
types during vessel formation, but also
maturation, stabilization, and remodeling
during later stages of vessel morphogen-
esis. Multiple factors are involved in this
crosstalk. For example, endothelial cells
signal to pericytes via production of
PDGF-BB and Notch ligands, among
other factors, while pericyte-derived an-
giopoetin-1 and TGFb are important
signaling entities for endothelial cells
(Armulik et al., 2005). The specificity and
temporal significance of these various
signals are still subjects of active
investigation.
Pericytes exhibit tremendous plasticity
in both their differentiation potential
and their developmental origins (Armulik
et al., 2011). The mesenchymal stem
cell nature of pericytes (Caplan, 2008) is
highlighted by several recent papers
demonstrating the ability of pericytes to
give rise to a variety of mesenchymal
cell types in different organs, including
skeletal muscle, smooth muscle, bone,
cartilage, and adipose tissue (Brachvogel
et al., 2005; Crisan et al., 2008). Develop-
mentally, pericytes can arise not only
from stem cell sources such as the bone
marrow, but also from cells that reside
in mature tissues such as adipose
deposits and both skeletal and smooth
muscles (Rajantie et al., 2004; Traktuev
et al., 2008). The laboratory of Giullio
Cossu has contributed to both sides
of the pericyte story. Previously they
demonstrated that pericytes in skeletalmuscle could serve as myogenic
precursor cells, distinct from but in
parallel with the activities of more well-
studied skeletal muscle satellite cells
(Dellavalle et al., 2007). This group now
reports, in this issue of Developmental
Cell, the ability of vascular endothelial
cells to convert skeletal muscle
myoblasts into pericytes (Cappellari
et al., 2013), emphasizing the bidirec-
tional plasticity that exists within mesen-
chymal lineages.
Cossu’s group noticed that when GFP-
tagged embryonic mouse myoblasts
(embryonic day 11.5) were cultured with
human umbilical vein endothelial cells
(HUVECs), the myoblasts began to
express the pericyte marker alkaline
phosphatase. Replacement of HUVECs
with the endothelial cell products PDGF-
BB and Notch ligand Dll4 led to complete
inhibition of myoblast fusion, retention
of proliferative ability, and upregulation
of several pericyte markers, including
alkaline phosphatase, RGS5, and NG2.
While PDGF-BB alone was unable to
produce these effects, Dll4 proved to be
active in producing a pericyte phenotype
(although with reduced potency) even in
the absence of PDGF-BB and could not
be replaced by other Notch ligands such
as Dll1 or Jagged1. In addition, inhibition
of Notch signaling blocked the expression
of pericyte markers and allowed rapid
myoblast fusion. Later-stage myoblasts
(embryonic day 16.5) express the Myf5
transcription factor, indicative of greater
commitment to a myogenic fate. Even at
this later stage, however, treatment of
myoblasts with Dll4 and PDGF-BB was
still able to block myoblast fusion and
induce pericyte marker expression.
Thus, the phenotypic switch from
myoblast to pericyte is not restricted to
very early-stage myoblasts, but can stillDevelopmental Cell 2be induced at fairly advanced stages of
myoblast commitment.
These observations raised the question
of whether Dll4/PDGF-BB treatment of
myoblasts produced a functional pericyte
phenotype in addition to the marker
phenotype. Pericytes essentially are
defined by their perivascular location
and by their ability to collaborate with
endothelial cells in forming functional
vascular tubes. When cultured in Matrigel
with HUVECs, GFP-positive Dll4/PDGF-
BB-treated myoblasts closely associated
with the endothelial cells to form vessel-
like networks that were stable for up to
2 weeks. This behavior mimicked that of
bona fide pericytes, but was not repro-
duced by untreated myoblasts, which
failed to stabilize endothelial networks.
Moreover, subcutaneous implantation
of Matrigel plugs containing HUVECs
and Dll4/PDGF-BB-treated GFP-positive
cells led to the formation in the plug
of functional vasculature composed of
the HUVECs and myoblast-derived peri-
cytes. This process could be blocked by
silencing HUVEC expression of Dll4 via
shRNA treatment, showing that, while
pretreatment of myoblasts with Dll4
was required to produce the angiogenic
effect, HUVEC-derived Dll4 was also
required for stabilizing and maintaining
the pericyte/endothelial cell relationship
in vivo.
In establishing the in vivo relevance of
these findings, the Cossu group also
demonstrated the presence of myogenic
markers in rare perivascular cells, sug-
gesting the possibility that pericytes may
occasionally be derived from myoblasts
during normal development. Pursuing
this further, they developed a mouse
model that allowed them to test the
effects of increased Notch signaling on
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phenotype. The model utilized RosaNICD
transgenic mice that express the Notch
Intracellular Domain (NICD) following
Cre-mediated recombination. Crossing
these mice with MyoDCre partners thus
activated Notch signaling specifically in
MyoD-expressing myoblasts. Although
some indications of an altered phenotype
in mutant embryos were seen at embry-
onic day 11.5, obvious changes were
not evident until embryonic day 13.5.
Numbers and/or size of myosin heavy
chain (MyHC)-positive myofibers were
significantly reduced in mutant embryos
at this stage, and perivascular cells
expressing both Myf5 and alkaline phos-
phatase were easily detectable in mutant,
but not control, embryos. By embryonic
day 16.5, the altered phenotype was
muchmore prominent in mutant embryos.
Skeletal muscle development was
severely reduced, while the pericyte
markers PDGFRb and alkaline phos-
phatase were clearly upregulated in
perivascular cells. In addition, elevated
Dll4 expression was observed in asso-
ciation with blood vessels, consistent
with its proposed role in myoblast con-
version to pericytes. The condition of
mutant embryos continued to deteriorate
at embryonic day 18.5, and the animals
died at birth. Beyond their reduced
skeletal muscle development, mutant
embryos exhibited prominent edema.
One possible explanation for this could
be impaired vascular function (increased
vessel leakiness). Thus, even though564 Developmental Cell 24, March 25, 2013 ªmyoblast-derived pericytes appear
capable of competing with normally
derived pericytes for perivascular locali-
zation, they nevertheless may not fully
mimic the functional properties of peri-
cytes derived from normal developmental
sources. It is intriguing to wonder whether
the function of myoblast-derived peri-
cytes is influenced by retention of certain
aspects of their myogenic identity (for
example continued expression of Myf5).
Additional studies of vascular function,
including evidence of increased hemor-
rhage, would have been a valuable addi-
tion to this work.
The authors suggest that the observed
mechanisms may be relevant to
myoblasts located at the boundary
between myogenic and angiogenic
tissues, where the balance of myogenic
versus angiogenic factors determines
their developmental fate. Under normal
conditions, this balance appears to be
heavily weighted toward a myogenic
fate, as evidenced by the scarcity of
myoblast-derived perivascular cells.
However, in pathological situations that
require the formation of new blood
vessels, the balance may swing toward
an angiogenic fate under the influence of
factors produced by activated vascular
endothelial cells. This story highlights the
bidirectional developmental plasticity of
mesenchymal cells because Cossu and
colleagues have previously reported the
ability of pericytes to generate myoblasts
(Dellavalle et al., 2007). This group has
also demonstrated the potential thera-2013 Elsevier Inc.peutic utility of pericyte transplantation
for treating muscle disorders (Tedesco
and Cossu, 2012). At this stage, it is
unclear to what extent myoblast trans-
plantation could be an effective strategy
for proangiogenic therapy.REFERENCES
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